Foundation Medicine and Flatiron Health are introducing a novel capability for supporting companion diagnostic regulatory filings with real-world data from the Flatiron Health-Foundation Medicine Clinico-Genomic Database.
In this Q&A, Igor Genkin, medical director at Salem Regional Cancer Center, discusses a minimally invasive test detecting 3D genomic markers that returns a binary result to the ordering physician with high accuracy: “low probability” or “high probability” of response to any immune checkpoint inhibitors.
Cell therapy has the potential to create highly innovative, life-changing medicines with never-before-achieved therapeutic and curative potential, but fragmented processes and inefficient data management can slow down cell therapy pipelines.
The resultsadd to evidence for the potential of ctDNA tumor fraction as a new monitoring tool that could allow clinical researchers to detect tumor progression and change treatment strategies earlier than through current methods.
DNA methylation analysis in the blood, powered by advances in wet-lab chemistry and bioinformatics, has enabled the use of epigenomic profiling to enhance the sensitivity of liquid biopsy, providing a deeper understanding of tumor biology and expanding the promise of precision oncology beyond what genomic information can offer.
